192 results on '"Prudkin, Ludmila"'
Search Results
2. Use of Topical Corticosteroids in the Treatment of Noninfectious Inflammatory Dermatoses of the Scalp: A Survey of Practicing Dermatologists and Dermatology Residents Using Delphi Methodology
3. Use of Topical Corticosteroids in the Treatment of Noninfectious Inflammatory Dermatoses of the Scalp: A Survey of Practicing Dermatologists and Dermatology Residents Using Delphi Methodology
4. Exposome Impact on Nail Health.
5. Data from Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
6. Supplementary Figure Legends 1-3 from Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
7. Supplementary Figure 3 from Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
8. Supplementary Figure 2 from Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
9. Data from Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel HER2V659E Mutation
10. Supplementary Data from Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel HER2V659E Mutation
11. Supplementary Figure 1 from Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
12. Supplementary Table 1 from Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel HER2V659E Mutation
13. Supplementary Figures from Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel HER2V659E Mutation
14. Supplementary Figure S1 from High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab
15. Supplementary Table 2 from A Pharmacodynamic/Pharmacokinetic Study of Ficlatuzumab in Patients with Advanced Solid Tumors and Liver Metastases
16. Supplementary Figure 4 from Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
17. Supplementary Figure 3 from A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors
18. Supplementary Figure 1 from Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
19. Supplementary Figure 2 from Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
20. Supplementary Figure 2 from A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors
21. Supplementary Data from Loss and Reduction of Fus1 Protein Expression is a Frequent Phenomenon in the Pathogenesis of Lung Cancer
22. Supplementary Table 3 from A Pharmacodynamic/Pharmacokinetic Study of Ficlatuzumab in Patients with Advanced Solid Tumors and Liver Metastases
23. Supplementary Table S1 from High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab
24. Supplementary Table 1 from A Pharmacodynamic/Pharmacokinetic Study of Ficlatuzumab in Patients with Advanced Solid Tumors and Liver Metastases
25. Supplementary Data from Clinical Benefit of Lapatinib-Based Therapy in Patients with Human Epidermal Growth Factor Receptor 2–Positive Breast Tumors Coexpressing the Truncated p95HER2 Receptor
26. Supplementary Table 1 from Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
27. Supplementary Table 4 from Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
28. Supplementary Table 2 from Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
29. Data from Loss and Reduction of Fus1 Protein Expression is a Frequent Phenomenon in the Pathogenesis of Lung Cancer
30. Supplementary Figure 1 from A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors
31. Supplementary Data from Immunohistochemical Expression of Estrogen and Progesterone Receptors Identifies a Subset of NSCLCs and Correlates with EGFR Mutation
32. Supplementary Figure 3 from Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
33. Supplementary Table 6 from Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
34. Supplementary Data from Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
35. Supplementary Table 5 from Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
36. Supplementary Table 3 from Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068
37. Data from Elevated Epithelial Insulin-like Growth Factor Expression Is a Risk Factor for Lung Cancer Development
38. Supplementary Figures 1-6, Tables 1-2 from Elevated Epithelial Insulin-like Growth Factor Expression Is a Risk Factor for Lung Cancer Development
39. Supplementary Figures 1-6 from A Peptide Selected by Biopanning Identifies the Integrin αvβ6 as a Prognostic Biomarker for Nonsmall Cell Lung Cancer
40. Supplementary Figure Legends 1-6 from A Peptide Selected by Biopanning Identifies the Integrin αvβ6 as a Prognostic Biomarker for Nonsmall Cell Lung Cancer
41. Prognostic Significance of Combinations of RNA-Dependent Protein Kinase and EphA2 Biomarkers for NSCLC
42. Obstacles to precision oncology: confronting current factors affecting the successful introduction of biomarkers to the clinic
43. Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2⁺ breast cancer patients
44. TGF-β Receptor Inhibitors Target the CD44 high/Id1 high Glioma-Initiating Cell Population in Human Glioblastoma
45. Corrigendum: mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer
46. Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung
47. RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer
48. The exposome impact on hair health: non-pharmacological management. Part II⋆
49. mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer
50. Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.